AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

07-Apr-2015 - USA

AmpliPhi BioSciences Corporation announced that the European Patent Office (EPO) has granted European patent no. EP 2570130, “Bacteriophage-containing Therapeutic Agents”. Three related patents have been issued in the United States (U.S. Patent Nos. 7,807,149, 8,105,579, and 8,388,946), the earliest of which was previously granted in 2010.

The claims of the European patent cover various bacteriophage preparations for use in combination with antibiotics for the treatment of biofilm-related infections caused by the bacterium Pseudomonas aeruginosa. The patent claims protect the Company’s proprietary methods of bacteriophage-based treatment of bacterial infection characterized by biofilms where P. aeruginosa is present, covering the application of one or more bacteriophage preparations which target and kill P. aeruginosa in the biofilm, followed by antibiotic treatment once bacteriophage replication is established. Examples of specific treatment regimens covered include the treatment of human and animal infections resulting from a skin burn or skin wound, lung infections such as hospital acquired pneumonia (HAP) and cystic fibrosis (CF), urinary tract infection (UTI) or an infection associated with a medical device or implant. Such infections are difficult to treat as they are often resistant to antibiotic therapy.

AmpliPhi is currently developing AmpliPhage-001, a proprietary mixture of bacteriophage targeting P. aeruginosa infections in patients with CF. In collaboration with the Royal Brompton NHS Hospital London, AmpliPhage-001 is expected to enter clinical studies next year.

https://www.bionity.com/en/news/152308/ampliphi-granted-european-patent-for-bacteriophage-therapy-to-fight-biofilm-related-bacterial-infections.html